DVA · Davita Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.42B | - | $3.42B | $3.38B | $3.22B | - | $3.26B | $3.19B | $3.07B | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $421.91M | - | $414.37M | $412.81M | $374.09M | - | $393.53M | $367.85M | $362.48M | - |
| Total Operating Expenses | $2.93B | - | $2.91B | $2.84B | $2.78B | - | $2.73B | $2.68B | $2.59B | - |
| D&A | $177.83M | - | $177.49M | $174.70M | $176.45M | - | $187.01M | $175.66M | $187.08M | - |
| Operating Income | $481.89M | - | $505.77M | $537.84M | $438.94M | - | $534.88M | $506.40M | $483.85M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $66.20M | - | $68.55M | $93.71M | $54.12M | - | $77.67M | $71.69M | $65.81M | - |
| Net Income | $197.53M | - | $150.33M | $199.34M | $162.92M | - | $214.69M | $222.68M | $239.65M | - |
| EPS - Basic | $2.93 | - | $2.09 | $2.62 | $2.05 | - | $2.56 | $2.56 | $2.73 | - |
| EPS - Diluted | $2.87 | - | $2.04 | $2.58 | $2.00 | - | $2.50 | $2.50 | $2.65 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $644.24M | $676.44M | $705.96M | $708.42M | $438.78M | $794.93M | $1.07B | $416.49M | $345.13M | $380.06M |
| Accounts Receivable | $2.46B | $2.41B | $2.33B | $2.44B | $2.32B | $2.15B | $2.27B | $2.30B | $2.59B | $1.99B |
| Inventory | $141.61M | $160.63M | $139.09M | $146.29M | $150.52M | $134.56M | $129.00M | $126.77M | $145.81M | $143.10M |
| Accounts Payable | $691.26M | $696.15M | $655.60M | $594.40M | $596.14M | $547.20M | $488.24M | $493.53M | $489.88M | $514.53M |
| Current Assets | $4.06B | $4.06B | $4.11B | $4.09B | $3.64B | $3.75B | $4.04B | $3.47B | $3.68B | $3.14B |
| Total Assets | $17.50B | $17.48B | $17.56B | $17.49B | $17.12B | $17.29B | $17.50B | $17.03B | $17.43B | $16.89B |
| Current Liabilities | $2.87B | $3.14B | $3.02B | $2.93B | $2.91B | $2.97B | $2.94B | $2.99B | $2.58B | $2.64B |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $16.45B | $16.32B | $16.22B | $15.94B | $15.46B | $15.19B | $15.28B | $14.60B | $14.79B | $14.15B |
| Stockholders' Equity | ($755.50M) | ($651.08M) | ($571.87M) | ($369.63M) | ($267.10M) | $121.12M | $386.71M | $632.90M | $926.00M | $1.06B |
| Retained Earnings | ($179.24M) | ($328.43M) | $2.05B | $1.90B | $1.70B | $1.53B | $1.28B | $1.06B | $837.94M | $598.29M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $320.83M | - | - | - | $180.01M | - | - | - | ($134.84M) | - |
| Investing Cash Flow | ($139.09M) | - | - | - | ($162.14M) | - | - | - | ($215.21M) | - |
| Financing Cash Flow | ($213.34M) | - | - | - | ($382.54M) | - | - | - | $319.32M | - |
| CapEx | $102.02M | - | - | - | $143.26M | - | - | - | $121.02M | - |
| Free Cash Flow | $218.81M | - | - | - | $36.75M | - | - | - | ($255.85M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 14.1% | - | 14.8% | 15.9% | 13.6% | - | 16.4% | 15.9% | 15.8% | - |
| EBITDA margin | 19.3% | - | 20.0% | 21.1% | 19.1% | - | 22.1% | 21.4% | 21.9% | - |
| Net margin | 5.8% | - | 4.4% | 5.9% | 5.1% | - | 6.6% | 7.0% | 7.8% | - |
| Free cash flow margin | 6.4% | - | - | - | 1.1% | - | - | - | -8.3% | - |
| FCF / Net income | 1.11 | - | - | - | 0.23 | - | - | - | -1.07 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 12.4% | - | 12.1% | 12.2% | 11.6% | - | 12.1% | 11.5% | 11.8% | - |
| Effective tax rate | 25.1% | - | 31.3% | 32.0% | 24.9% | - | 26.6% | 24.4% | 21.5% | - |
| Return on assets | 1.1% | - | 0.9% | 1.1% | 1.0% | - | 1.2% | 1.3% | 1.4% | - |
| Return on equity | -26.1% | - | -26.3% | -53.9% | -61.0% | - | 55.5% | 35.2% | 25.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.42 | 1.29 | 1.36 | 1.39 | 1.25 | 1.26 | 1.37 | 1.16 | 1.43 | 1.19 |
| Quick ratio | 1.37 | 1.24 | 1.32 | 1.34 | 1.20 | 1.21 | 1.33 | 1.12 | 1.37 | 1.13 |
| Cash ratio | 0.22 | 0.22 | 0.23 | 0.24 | 0.15 | 0.27 | 0.36 | 0.14 | 0.13 | 0.14 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -23.16 | -26.85 | -30.70 | -47.33 | -64.09 | 142.71 | 45.26 | 26.90 | 18.82 | 16.00 |
| Liabilities / Assets | 0.94 | 0.93 | 0.92 | 0.91 | 0.90 | 0.88 | 0.87 | 0.86 | 0.85 | 0.84 |
| Efficiency | ||||||||||
| Asset turnover | 0.20 | - | 0.19 | 0.19 | 0.19 | - | 0.19 | 0.19 | 0.18 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 263d | - | 249d | 264d | 263d | - | 254d | 264d | 308d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 53.6x | - | 65.1x | 55.2x | 76.5x | - | 65.6x | 55.4x | 52.1x | - |
| P / B | - | - | - | - | - | - | 36.4x | 19.5x | 13.5x | - |
| P / S | 3.1x | - | 2.9x | 3.3x | 3.9x | - | 4.3x | 3.9x | 4.1x | - |
| EV / EBITDA | 15.1x | - | 13.3x | 14.5x | 19.5x | - | 18.0x | 17.5x | 18.1x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 6.0% | - | 4.8% | 6.1% | 5.0% | - | 4.6% | 6.2% | 6.9% | - |
| Revenue CAGR (3y) | 5.9% | - | 5.1% | 4.9% | 4.6% | - | 3.6% | 3.0% | 2.9% | - |
| Revenue CAGR (5y) | 3.9% | - | 3.2% | 3.3% | 2.6% | - | 2.4% | 2.3% | 2.3% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 9.8% | - | -5.4% | 6.2% | -9.3% | - | 7.9% | 24.9% | 55.3% | - |
| Net income growth (YoY) | 21.2% | - | -30.0% | -10.5% | -32.0% | - | -13.0% | 24.6% | 107.4% | - |
| EPS growth (YoY) | 43.5% | - | -18.4% | 3.2% | -24.5% | - | -4.6% | 30.9% | 112.0% | - |
| EPS CAGR (3y) | 31.9% | - | 21.8% | 3.9% | 7.5% | - | 1.9% | -1.8% | 8.2% | - |
| EPS CAGR (5y) | 6.5% | - | 9.8% | 9.8% | 1.1% | - | 21.4% | 8.8% | 24.1% | - |
| FCF growth (YoY) | 495.4% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | 87.7% | - | - | - | -29.1% | - | - | - | - | - |
| Book value growth (YoY) | -182.9% | - | - | - | - | -88.5% | -67.8% | -37.8% | 12.2% | 48.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$13.64B totalUSDialysis And Related Lab Services With Intersegment$11.79B · 86.4%
Other Operating Segments With Intersegment$1.92B · 14.1%
All Other Segments($11.20M) · -0.1%
USDialysis And Related Lab Services($60.96M) · -0.4%
Peer comparison
Same SIC group: Services-Misc Health & Allied Services, NEC
Comparing DAVITA INC. against the 5 most active filers in the same SIC group.